# AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Source: https://onco.cc/trials/nct07038343/  
OnCo record `nct07038343` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AVZO-1418 in biliary tract cancer, bladder & urothelial cancer and nasopharyngeal carcinoma, run by Avenzo Therapeutics, Inc., now recruiting.

## Summary

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) is a phase 1/2 interventional study registered as NCT07038343 by Avenzo Therapeutics, Inc., with 480 participants planned, started 2025-06-04 and due to reach its primary completion in 2030-06. Interventions recorded: AVZO-1418, Combination Agent 1 and Combination Agent 2.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07038343
- Phase: 1/2
- Setting: A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Avenzo Therapeutics, Inc.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT07038343: https://clinicaltrials.gov/study/NCT07038343

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/)

---
JSON: https://onco.cc/api/v1/entities/nct07038343.json